Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA4 Biologics Sequence Review Report 2026: Ephrin-A4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA3 Biologics Sequence Review Report 2026: Ephrin-A3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EFNA1 Biologics Sequence Review Report 2026: Ephrin-A1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL9 Biologics Sequence Review Report 2026: C-X-C motif chemokine 9 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
256
257
258
259
260
>>
1670
>